CKD 581

Drug Profile

CKD 581

Alternative Names: CKD-581

Latest Information Update: 18 Feb 2017

Price : $50

At a glance

  • Originator Chong Kun Dang
  • Class Antineoplastics
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Lymphoma; Multiple myeloma

Most Recent Events

  • 01 Jan 2017 Phase-I clinical trials in Multiple myeloma (Second-line therapy or greater, Combination therapy) in South Korea (Parenteral) (NCT03051841)
  • 10 Oct 2016 Chong Kun Dang completes a phase I trial for Lymphoma and Multiple myeloma (Second-line therapy or greater) in South Korea (NCT01580371)
  • 05 Apr 2016 Phase I development is ongoing in South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top